We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.19B
AUM Growth
+$35.3M
Cap. Flow
+$22.8M
Cap. Flow %
0.54%
Top 10 Hldgs %
34.58%
Holding
124
New
4
Increased
47
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$19.7M
2
RVMD icon
Revolution Medicines
RVMD
+$17.3M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.3M
4
PLRX icon
Pliant Therapeutics
PLRX
+$14M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.7M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$58.6M
2
PEN icon
Penumbra
PEN
+$19.1M
3
IMCR icon
Immunocore
IMCR
+$18M
4
ALGN icon
Align Technology
ALGN
+$16.2M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Consumer Staples 1.05%
3 Industrials 0.87%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$33.1B
$57M 1.36%
490,500
– –
AKRO
27
DELISTED
Akero Therapeutics
AKRO
$55.6M 1.33%
1,454,254
+53,600
+4% +$2.39M
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.64B
$53.6M 1.28%
1,336,401
+46,122
+4% +$1.98M
EW icon
29
Edwards Lifesciences
EW
$53B
$53.4M 1.27%
645,900
– –
ASND icon
30
Ascendis Pharma A/S
ASND
$16.8B
$45.6M 1.09%
425,500
– –
FRPT icon
31
Freshpet
FRPT
$3.26B
$43.9M 1.05%
662,500
+5,500
+0.8% +$338K
MIRM icon
32
Mirum Pharmaceuticals
MIRM
$6.02B
$43.1M 1.03%
1,795,733
– –
AMLX icon
33
Amylyx Pharmaceuticals
AMLX
$2.53B
$42.6M 1.02%
1,452,816
+223,179
+18% +$7.75M
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.21B
$42.2M 1.01%
1,178,002
+2,330
+0.2% +$86.1K
PCRX icon
35
Pacira BioSciences
PCRX
$974M
$42.1M 1.01%
1,032,600
– –
PHR icon
36
Phreesia
PHR
$769M
$42.1M 1%
1,302,500
– –
BMEA icon
37
Biomea Fusion
BMEA
$92.1M
$40.2M 0.96%
1,297,213
+566,367
+77% +$7.04M
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$39.6M 0.95%
1,065,261
+260,237
+32% +$11.7M
NVRO
39
DELISTED
NEVRO CORP.
NVRO
$39M 0.93%
1,077,900
– –
IRTC icon
40
iRhythm Holdings
IRTC
$4.1B
$38.4M 0.92%
309,450
– –
OLK
41
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$37.2M 0.89%
1,650,000
+205,000
+14% +$4.46M
ACCD
42
DELISTED
Accolade Inc
ACCD
$36.6M 0.87%
2,545,000
+607,000
+31% +$6.87M
PRTA icon
43
Prothena Corp
PRTA
$468M
$36.5M 0.87%
753,462
– –
KYMR icon
44
Kymera Therapeutics
KYMR
$9.03B
$36.4M 0.87%
1,228,379
+600
+0% +$19.4K
ZLAB icon
45
Zai Lab
ZLAB
$2.65B
$35.2M 0.84%
1,059,700
– –
ACRS icon
46
Aclaris Therapeutics
ACRS
$867M
$32.1M 0.76%
3,961,849
+600
+0% +$7.62K
ABCM
47
DELISTED
Abcam PLC
ABCM
$30.2M 0.72%
2,242,500
+62,500
+3% +$933K
TVTX icon
48
Travere Therapeutics
TVTX
$5.74B
$28.7M 0.69%
1,276,650
+325,000
+34% +$6.91M
RYTM icon
49
Rhythm Pharmaceuticals
RYTM
$7.95B
$28.5M 0.68%
1,597,123
-163,742
-9% -$4.11M
XLV icon
50
State Street Health Care Select Sector SPDR ETF
XLV
$44B
$25.9M 0.62%
200,000
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rock Springs Capital Management held 124 positions worth $4.19B, up 0.85% from $4.16B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q1 2023 filing shows 4 new, 47 increased, 8 reduced and 3 closed positions. Its largest new stake was Mineralys Therapeutics: 1,167,492 shares worth $18.3M. The largest sale was Baxter International, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2023 buy was Mineralys Therapeutics: 1,167,492 shares worth $18.3M.
  • Rock Springs Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q1 2023, an estimated $15.3M increase.
  • Rock Springs Capital Management's biggest Q1 2023 reduction was Penumbra, cutting an estimated $19.1M.
  • Rock Springs Capital Management fully exited Baxter International in Q1 2023, selling an estimated $58.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $4.19B portfolio in Q1 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 3 in Q1 2023.
  • Rock Springs Capital Management's portfolio value rose 0.85% quarter-over-quarter to $4.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2023, filed 15 May 2023.